LW-1017, an orally available small molecule that activates the lysosomal channel TRPML1, reduced Parkinson's and Alzheimer's pathology and improved motor and cognitive performance in aged mouse models, according to a paper in Scientific Reports. The drug restored autophagy–lysosomal clearance of alpha-synuclein, amyloid and tau, with effects absent when TRPML1 was removed. Findings are preclinical; the compound is currently in a Phase I ascending-dose study in healthy volunteers.
Key Points
- TRPML1 activation restored lysosomal clearance in aged Alzheimer's and Parkinson's mice
- Reduced alpha-synuclein, amyloid and tau; improved movement and memory
- Brain penetrance drove efficacy; Phase I in healthy volunteers underway
Longevity Analysis
Proteostasis failure — the progressive decline in the cell's capacity to degrade and recycle damaged material — underlies much of age-related neurodegeneration, and targeting the lysosome directly addresses the removal step rather than the accumulated product. Autophagy is already modifiable through fasting windows, exercise, sleep depth and reduced chemical burden; a pharmacological lever on the same pathway would extend, not replace, those inputs. Effect sizes were not disclosed in the company release, and the gap between rodent neurodegeneration models and human outcomes remains the primary uncertainty.
Original published by Longevity.Technology, by Kyle Umipig.